2016 News Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
05/03/16Verastem Announces the Presentation of Clinical Data at iMig 2016
- VS-6063 generally well tolerated; early signs of tumor reduction observed - - Results from Cohort 2 continue encouraging observations from Cohort 1 for single-agent VS-6063 in chemotherapy-naïve patients as a neoadjuvant therapy - BOSTON--(BUSINESS WIRE)--May 3, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of clinical data by Professor Raphae... 
Printer Friendly Version
04/18/16Verastem Names Gregory I. Berk, MD as Chief Medical Officer
- Announces Additional Key Executive Management Appointments and Changes - BOSTON--(BUSINESS WIRE)--Apr. 18, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the appointment of Gregory I. Berk, MD as Chief Medical Officer. Dr. Berk will be responsible for leading the Company's global clinical development strategy and clinical operations. Dr. Berk replaces interim Chief Medical Of... 
Printer Friendly Version
04/18/16Verastem Co-Founder, Dr. Robert Weinberg, Recognized with Two Prestigious Cancer Research Awards
- Salk Institute Medal of Excellence and American Association of Cancer Research Lifetime Achievement Award for Cancer Research - BOSTON--(BUSINESS WIRE)--Apr. 18, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that Robert Weinberg, Ph.D., Verastem Co-founder and Chairman of the Scientific Advisory Board, and a pioneer in cancer research, was recently honored with the Salk Institute ... 
Printer Friendly Version
03/30/16Verastem Announces Presentation of Scientific Data Supporting FAK Inhibition in Combination with Immunotherapy at the Keystone Symposium on Cancer Pathophysiology
BOSTON--(BUSINESS WIRE)--Mar. 30, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the oral presentation of preclinical data by the Company’s scientific collaborator David G. DeNardo, PhD, Assistant Professor of Medicine, Division of Oncology, Department of Immunology, Washington University School of Medicine in St. Louis, at the Keystone Symposium on Cancer Pathophysiology being hel... 
Printer Friendly Version
03/22/16Verastem Announces Oral Presentation of Data Supporting the Preferential Targeting of Ovarian Cancer Stem Cells at the Society of Gynecologic Oncology’s 2016 Annual Meeting on Women’s Cancer
BOSTON--(BUSINESS WIRE)--Mar. 22, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of scientific data at the Society of Gynecologic Oncology’s 2016 Annual Meeting on Women’s Cancer being held March 19-22, 2016 in San Diego, CA. “The data presented today at SGO 2016 are important because they provide further scientific evidence that chemotherapy can lead to an increa... 
Printer Friendly Version
03/16/16Verastem to Present Data Supporting FAK/PYK2 Inhibition at the 2016 American Academy of Cancer Research Annual Meeting
BOSTON--(BUSINESS WIRE)--Mar. 16, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of scientific data at the 2016 American Association of Cancer Research (AACR) Annual Meeting being held April 16-20, 2016 in New Orleans, LA. “The data that will be presented at the upcoming 2016 AACR Annual Meeting continue to build on the premise that focal adhesion kinase (F... 
Printer Friendly Version
03/10/16Verastem to Present Scientific Data Supporting FAK and PI3K/mTOR Inhibition to Target Cancer Stem Cells at the Keystone Symposium on Stem Cells and Cancer
BOSTON--(BUSINESS WIRE)--Mar. 10, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of preclinical data and participation in an expert panel at the Keystone Symposium on Stem Cells and Cancer being held March 6 – 10, 2016 in Breckenridge, CO. “The scientific consensus on the importance of targeting cancer stem cells to enable a durable clinical response continues to ... 
Printer Friendly Version
03/08/16Verastem to Present at 28th Annual ROTH Conference
BOSTON--(BUSINESS WIRE)--Mar. 8, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the Company will present at the 28th Annual ROTH Conference on Tuesday, March 15 at 12:00 p.m. PT at the Ritz-Carlton in Dana Point, CA. A live webcast of the presentation will be available on the company's website at www.verastem.com. An archived presentation will be available for 90 days.... 
Printer Friendly Version
03/03/16Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Collaboration will focus on a Phase I/Ib clinical trial expected to begin in the second half of 2016 DARMSTADT, Germany & NEW YORK & BOSTON--(BUSINESS WIRE)--Mar. 3, 2016-- Merck, Pfizer and Verastem announced today that they have entered into an agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem’s VS-6063**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer.... 
Printer Friendly Version
03/03/16Verastem Reports Year-End 2015 Financial Results
BOSTON--(BUSINESS WIRE)--Mar. 3, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the year ended December 31, 2015, and also provided an overview of certain corporate developments. “We are developing treatments that reduce cancer stem cells and modulate the local tumor microenvironment to allow both cancer treatments and the immune system to do their job ... 
Printer Friendly Version
03/01/16Verastem to Host Conference Call on March 3rd to Discuss Fourth Quarter and Full-Year 2015 Financial Results and Recent Highlights
BOSTON--(BUSINESS WIRE)--Mar. 1, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the Company will host a conference call and webcast on Thursday, March 3, 2016 at 8:30 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter year ended December 31, 2015. The call can be accessed by dialing (877) 341-5660 (U.S. and Canada) or (315) 625-... 
Printer Friendly Version
01/27/16Verastem to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Jan. 27, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming investor conferences: 18th Annual BIO CEO & Investor Conference on Tuesday, February 9 at 8:00 a.m. ET at the Waldorf Astoria Hotel in New York City Leerink Partners 5th Annual Global Healthcare Conferen... 
Printer Friendly Version
01/21/16Verastem to Present Scientific Data Supporting FAK Inhibition in Combination with Immune Checkpoint Inhibitors at Immunotherapy World 2016
BOSTON--(BUSINESS WIRE)--Jan. 21, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of preclinical data and participation in an expert panel at Immunotherapy World 2016 being held January 25-27, 2016 in Washington, DC. “Over the past couple of years, exciting data have emerged from several research groups demonstrating the importance of FAK inhibition in the i... 
Printer Friendly Version
01/06/16Washington University in St. Louis Initiates Clinical Study of Verastem’s VS-6063 in Combination with Merck’s Pembrolizumab and Gemcitabine in Pancreatic Cancer
BOSTON--(BUSINESS WIRE)--Jan. 6, 2016-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced the initiation of a Phase 1 dose-escalation study at Washington University to evaluate Verastem’s FAK inhibitor VS-6063 in combination with Merck’s PD-1 inhibitor pembrolizumab and gemcitabine in patients with pancreatic cancer. This is the first of several combination clinical trials the Company expects ... 
Printer Friendly Version